

Schizophrenia Bulletin

Index—1982-83

Author Index

A

- Abbott, D.; Rotnem, D.; Genel, M.; and Cohen, D.J.** Cognitive and emotional functioning in hypopituitary short-statured children, 8(2):310-319, 1982.
- Anderson, G.M., and Young, J.G.** Determination of neurochemically important compounds in physiological samples using HPLC, 8(2):333-348, 1982.
- Anderson, G.M.;** *see* Young, J.G.
- Anonymous.** First person account: A father's thoughts, 9(3):439-442, 1983.
- Anonymous.** First person account: A glimmer of light in the dark, 9(2):284-286, 1983.
- Anonymous.** First person account: Schizophrenia—A pharmacy student's view, 9(1):152-155, 1983.
- Anthony, W.A., and Farkas, M.** A client outcome planning model for assessing psychiatric rehabilitation interventions, 8(1):13-38, 1982.

B

- Bachrach, L.L.** Assessment of outcomes in community support systems: Results, problems, and limitations, 8(1):39-61, 1982.
- Baldessarini, R.J.** Letter to the editor, 8(4):529, 1982.
- Baldessarini, R.J.;** *see* Donaldson, S.R.
- Bartko, J.J.;** *see* Carpenter, W.T., Jr.
- Berner, P.;** *see* Schanda, H.
- Bernheim, K.F.** Supportive family counseling, 8(4):634-641, 1982.
- Blashfield, R.K.** Feighner et al., invisible colleges, and the Matthew effect, 8(1):1-6, 1982.
- Bleich, A.** Letter to the editor, 9(3):329, 1983.
- Bowers, M.B., Jr.** What is schizophrenia?, 9(4):495-497, 1983.
- Brockington, I.F., and Meltzer, H.Y.** Documenting an episode of psychiatric illness: Need for multiple information sources, multiple raters, and narrative, 8(3):485-492, 1982.
- Bruder, G.E.** Cerebral laterality and psychopathology: A review of dichotic listening studies, 9(1):134-151, 1983.
- Brundage, B.E.** First person account: What I wanted to know but was afraid to ask, 9(4):583-585, 1983.

- Brunstetter, R.** Preface [to child psychiatry issue], 8(2):199-200, 1982.
- Buckley, P.** Identifying schizophrenic patients who should not receive medication, 8(3):429-432, 1982.

C

- Calev, A.; Venables, P.H.; and Monk, A.F.** Evidence for distinct verbal memory pathologies in severely and mildly disturbed schizophrenics, 9(2):247-264, 1983.
- Cannon-Spoor, H.E.; Potkin, S.G.; and Wyatt, R.J.** Measurement of premorbid adjustment in chronic schizophrenia, 8(3):470-484, 1982.
- Caparulo, B.K.;** *see* Young, J.G.
- Carbonari, C.M.;** *see* Harcherik, D.F.
- Carbonari, C.M.;** *see* Jagger, J.
- Carpenter, W.T., Jr.** What is schizophrenia?, 9(1):9-10, 1983.
- Carpenter, W.T., Jr.; Bartko, J.J.; and St. Claire Evans, M.** Multivariate statistics and meaning in the study of psychopathology, 9(1):1-6, 1983.
- Carpenter, W.T., Jr., and Heinrichs, D.W.** Early intervention, time limited, targeted pharmacotherapy of schizophrenia, 9(4):533-542, 1983.
- Carpenter, W.T., Jr.;** *see* Pulver, A.E.
- Carpenter, W.T., Jr.;** *see* Schooler, N.R.
- Carr, V.J.** Recovery from schizophrenia: A review of patterns of psychosis, 9(1):95-121, 1983.
- Chaika, E.** Thought disorder or speech disorder in schizophrenia?, 8(4):587-591, 1982.
- Cohen, D.J.** Clinical research in child psychiatry—Methods and strategies, 8(2):201-204, 1982.
- Cohen, D.J.;** *see* Abbott, D.
- Cohen, D.J.;** *see* Harcherik, D.F.
- Cohen, D.J.;** *see* Hunt, R.D.
- Cohen, D.J.;** *see* Jagger, J.
- Cohen, D.J.;** *see* Paul, R.
- Cohen, D.J.;** *see* Young, J.G.
- Cohen, P.;** *see* Engelhardt, D.M.
- Csernansky, J.G.; Holman, C.; and Hollister, L.E.** Variability and the dopamine hypothesis of schizophrenia, 9(3):325-328, 1983.

D

- Detlor, J.;** *see* Young, J.G.

Schizophrenia Bulletin

Index—1982-83

Author Index

A

- Abbott, D.; Rotnem, D.; Genel, M.; and Cohen, D.J.** Cognitive and emotional functioning in hypopituitary short-statured children, 8(2):310-319, 1982.
- Anderson, G.M., and Young, J.G.** Determination of neurochemically important compounds in physiological samples using HPLC, 8(2):333-348, 1982.
- Anderson, G.M.;** *see* Young, J.G.
- Anonymous.** First person account: A father's thoughts, 9(3):439-442, 1983.
- Anonymous.** First person account: A glimmer of light in the dark, 9(2):284-286, 1983.
- Anonymous.** First person account: Schizophrenia—A pharmacy student's view, 9(1):152-155, 1983.
- Anthony, W.A., and Farkas, M.** A client outcome planning model for assessing psychiatric rehabilitation interventions, 8(1):13-38, 1982.

B

- Bachrach, L.L.** Assessment of outcomes in community support systems: Results, problems, and limitations, 8(1):39-61, 1982.
- Baldessarini, R.J.** Letter to the editor, 8(4):529, 1982.
- Baldessarini, R.J.;** *see* Donaldson, S.R.
- Bartko, J.J.;** *see* Carpenter, W.T., Jr.
- Berner, P.;** *see* Schanda, H.
- Bernheim, K.F.** Supportive family counseling, 8(4):634-641, 1982.
- Blashfield, R.K.** Feighner et al., invisible colleges, and the Matthew effect, 8(1):1-6, 1982.
- Bleich, A.** Letter to the editor, 9(3):329, 1983.
- Bowers, M.B., Jr.** What is schizophrenia?, 9(4):495-497, 1983.
- Brockington, I.F., and Meltzer, H.Y.** Documenting an episode of psychiatric illness: Need for multiple information sources, multiple raters, and narrative, 8(3):485-492, 1982.
- Bruder, G.E.** Cerebral laterality and psychopathology: A review of dichotic listening studies, 9(1):134-151, 1983.
- Brundage, B.E.** First person account: What I wanted to know but was afraid to ask, 9(4):583-585, 1983.

- Brunstetter, R.** Preface [to child psychiatry issue], 8(2):199-200, 1982.
- Buckley, P.** Identifying schizophrenic patients who should not receive medication, 8(3):429-432, 1982.

C

- Calev, A.; Venables, P.H.; and Monk, A.F.** Evidence for distinct verbal memory pathologies in severely and mildly disturbed schizophrenics, 9(2):247-264, 1983.
- Cannon-Spoor, H.E.; Potkin, S.G.; and Wyatt, R.J.** Measurement of premorbid adjustment in chronic schizophrenia, 8(3):470-484, 1982.
- Caparulo, B.K.;** *see* Young, J.G.
- Carbonari, C.M.;** *see* Harcherik, D.F.
- Carbonari, C.M.;** *see* Jagger, J.
- Carpenter, W.T., Jr.** What is schizophrenia?, 9(1):9-10, 1983.
- Carpenter, W.T., Jr.; Bartko, J.J.; and St. Claire Evans, M.** Multivariate statistics and meaning in the study of psychopathology, 9(1):1-6, 1983.
- Carpenter, W.T., Jr., and Heinrichs, D.W.** Early intervention, time limited, targeted pharmacotherapy of schizophrenia, 9(4):533-542, 1983.
- Carpenter, W.T., Jr.;** *see* Pulver, A.E.
- Carpenter, W.T., Jr.;** *see* Schooler, N.R.
- Carr, V.J.** Recovery from schizophrenia: A review of patterns of psychosis, 9(1):95-121, 1983.
- Chaika, E.** Thought disorder or speech disorder in schizophrenia?, 8(4):587-591, 1982.
- Cohen, D.J.** Clinical research in child psychiatry—Methods and strategies, 8(2):201-204, 1982.
- Cohen, D.J.;** *see* Abbott, D.
- Cohen, D.J.;** *see* Harcherik, D.F.
- Cohen, D.J.;** *see* Hunt, R.D.
- Cohen, D.J.;** *see* Jagger, J.
- Cohen, D.J.;** *see* Paul, R.
- Cohen, D.J.;** *see* Young, J.G.
- Cohen, P.;** *see* Engelhardt, D.M.
- Csernansky, J.G.; Holman, C.; and Hollister, L.E.** Variability and the dopamine hypothesis of schizophrenia, 9(3):325-328, 1983.

D

- Detlor, J.;** *see* Young, J.G.

- Dibble, E.; *see* Schulz, P.M.
 Donaldson, S.R.; Gelenberg, A.J.; and Baldessarini, R.J. The pharmacologic treatment of schizophrenia: A progress report, 9(4):504-527, 1983.
 Dysken, M.W.; *see* Mueser, K.T.

E

- Engelhardt, D.M.; Rosen, B.; Feldman, J.; Engelhardt, J.A.Z.; and Cohen, P. A 15-year followup of 646 schizophrenic outpatients, 8(3):493-503, 1982.
 Engelhardt, J.A.Z.; *see* Engelhardt, D.M.
 Erlenmeyer-Kimling, L.; *see* Friedman, D.

F

- Faber, R. Letter to the editor, 8(4):594, 1982.
 Falloon, I.R.H., and Liberman, R.P. Interactions between drug and psychosocial therapy in schizophrenia, 9(4):543-554, 1983.
 Falloon, I.R.H.; *see* Vaughn, C.E.
 Farkas, M.; *see* Anthony, W.A.
 Feiz, R.; *see* Young, J.G.
 Feldman, J.; *see* Engelhardt, D.M.
 Fischmann, L.G. Dreams, hallucinogenic drug states, and schizophrenia: A psychological and biological comparison, 9(1):73-94, 1983.
 Fogg, L.; *see* Lewine, R.R.J.
 Freeman, W.; *see* Vaughn, C.E.
 Friedhoff, A.J. A strategy for developing novel drugs for the treatment of schizophrenia, 9(4):555-562, 1983.
 Friedman, D.; Vaughan, H.G., Jr.; and Erlenmeyer-Kimling, L. Cognitive brain potentials in children at risk for schizophrenia: Preliminary findings, 8(3):514-531, 1982.

G

- Gabriel, E.; *see* Schanda, H.
 Garbutt, J.C., and van Kammen, D.P. The interaction between GABA and dopamine: Implications for schizophrenia, 9(3):336-353, 1983.
 Garbutt, J.C.; *see* Wilson, I.C.
 Gelenberg, A.J.; *see* Donaldson, S.R.
 Genel, M.; *see* Abbott, D.
 Genel, M.; *see* Young, J.G.
 Gershon, E.S.; *see* Schulz, P.M.
 Goldstein, M.J. What is schizophrenia?, 8(4):600-602, 1982.

- Guy, J.D.; Majorski, L.V.; Wallace, C.J.; and Guy, M.P. The incidence of minor physical anomalies in adult male schizophrenics, 9(4):571-582, 1983.
 Guy, M.P.; *see* Guy, J.D.
 Guze, S.B. Comments on Blashfield's article, 8(1):6-7, 1982.

H

- Haracz, J.L. The dopamine hypothesis: An overview of studies with schizophrenic patients, 8(3):438-469, 1982.
 Harcherik, D.F.; Carbonari, C.M.; and Cohen, D.J. Attentional and perceptual measures: Developmental changes, 8(2):349-355, 1982.
 Harcherik, D.F.; Carbonari, C.M.; Shaywitz, S.E.; Shaywitz, B.A.; and Cohen, D.J. Attentional and perceptual disturbances in children with Tourette's syndrome, attention deficit disorder, and epilepsy, 8(2):356-359, 1982.
 Harcherik, D.F.; *see* Young, J.G.
 Harrow, M.; Lanin-Kettering, I.; Prosen, M.; and Miller, J.G. Disordered thinking in schizophrenia: Intermingling and loss of set, 9(3):354-367, 1983.
 Heinrichs, D.W.; *see* Carpenter, W.T., Jr.
 Hersh, S.; *see* Summers, F.
 Hoffman, D.F. Letter to the editor, 9(3):329-330, 1983.
 Holden, D.F., and Lewine, R.R.J. How families evaluate mental health professionals, resources, and effects of illness, 8(4):626-633, 1982.
 Hollister, L.E.; *see* Csernansky, J.G.
 Holman, C.; *see* Csernansky, J.G.
 Holzman, P.S. Smooth pursuit eye movements in psychopathology, 9(1):33-36, 1983.
 Holzman, P.S.; *see* Levy, D.L.
 Holzman, P.S.; *see* Lipton, R.B.
 Houghton, J.F. First person account: Maintaining mental health in a turbulent world, 8(3):548-552, 1982.
 Hunt, R.D.; Cohen, D.J.; Shaywitz, S.E.; and Shaywitz, B.A. Strategies for study of the neurochemistry of attention deficit disorder in children, 8(2):236-252, 1982.
 Hunt, R.D.; *see* Young, J.G.

I

- Iacono, W.G., and Lykken, D.T. The

- assessment of smooth tracking dysfunction, 9(1):44-50, 1983.
 Intagliata, J. Improving the quality of community care for the chronically mentally disabled: The role of case management, 8(4):655-674, 1982.

J

- Jagger, J.; Prusoff, B.A.; Cohen, D.J.; Kidd, K.K.; Carbonari, C.M.; and John, K. The epidemiology of Tourette's syndrome: A pilot study, 8(2):267-278, 1982.
 Jenner, F.A. Letter to the editor, 8(4):593-594, 1982.
 John, K.; *see* Jagger, J.
 Jones, S.; *see* Vaughn, C.E.

K

- Kane, J.M. Low dose medication strategies in the maintenance treatment of schizophrenia, 9(4):528-532, 1983.
 Katz, M.M. Comments on Blashfield's article, 8(1):9-11, 1982.
 Kavanagh, M.E.; *see* Young, J.G.
 Keith, S.J.; *see* Maser, J.D.
 Kendell, R.E. Comments on Blashfield's article, 8(1):11-12, 1982.
 Kety, S.S. What is schizophrenia?, 8(4):597-600, 1982.
 Kidd, K.K.; *see* Jagger, J.
 Kidd, K.K.; *see* Pauls, D.L.
 Kronberger, M.-L.; *see* Schanda, H.
 Küfferle, B.; *see* Schanda, H.
 Kyprie, R.M.; *see* Young, J.G.

L

- Lanier, C.F.; *see* Wilson, I.C.
 Lanin-Kettering, I.; *see* Harrow, M.
 Larson, J.; *see* Spohn, H.E.
 Leckman, J.F.; *see* Young, J.G.
 Levin, S. Smooth pursuit impairment in schizophrenia: What does it mean?, 9(1):37-44, 1983.
 Levin, S.; *see* Lipton, R.B.
 Levy, D.L.; Holzman, P.S.; and Proctor, L.R. Vestibular dysfunction and psychopathology, 9(3):383-438, 1983.
 Levy, D.L.; *see* Lipton, R.B.
 Lewine, R.R.J. A dialogue among patients, families, and professionals—Editor's introduction, 8(4):603-604, 1982.
 Lewine, R.R.J. Overview and reflections,

- 8(4):652-654, 1982.
- Lewine, R.R.J.; Fogg, L.; and Meltzer, H.Y. Assessment of negative and positive symptoms in schizophrenia, 9(3):368-376, 1983.
- Lewine, R.R.J.; *see* Holden, D.F.
- Liberman, R.P. Assessment of social skills, 8(1):62-84, 1982.
- Liberman, R.P. What is schizophrenia?, 8(3):435-437, 1982.
- Liberman, R.P.; *see* Falloon, I.R.H.
- Liberman, R.P.; *see* Vaughn, C.E.
- Lipton, R.B.; Levy, D.L.; Holzman, P.S.; and Levin, S. Eye movement dysfunctions in psychiatric patients: A review, 9(1):13-32, 1983.
- Lovejoy, M. Expectations and the recovery process, 8(4):605-609, 1982.
- Ludwig, A.M. What is schizophrenia?, 9(3):334-335, 1983.
- Lykken, D.T.; *see* Iacono, W.G.
- M**
- Majorski, L.V.; *see* Guy, J.D.
- Maser, J.D., and Keith, S.J. NIMH activities: CT scans and schizophrenia—Report on a workshop, 9(2):265-283, 1983.
- McGlashan, T.H. Apathy: The syndrome of pseudo-depression in chronic schizophrenia, 8(1):118-134, 1982.
- Meltzer, H.Y. What is schizophrenia?, 8(3):433-435, 1982.
- Meltzer, H.Y.; *see* Brockington, I.F.
- Meltzer, H.Y.; *see* Lewine, R.R.J.
- Mendelsohn, E., and Silverman, L.H. Effects of stimulating psychodynamically relevant unconscious fantasies on schizophrenic psychopathology, 8(3):532-547, 1982.
- Mikkelsen, E.J. Efficacy of neuroleptic medication in pervasive developmental disorders of childhood, 8(2):320-332, 1982.
- Miller, J.G.; *see* Harrow, M.
- Möller, H.-J., and von Zerssen, D. Depressive states occurring during the neuroleptic treatment of schizophrenia, 8(1):109-117, 1982.
- Möller, H.-J., von Zerssen, D.; Werner-Eilert, K.; and Wüschner-Stockheim, M. Outcome in schizophrenic and similar paranoid psychoses, 8(1):99-108, 1982.
- Monk, A.F.; *see* Calev, A.
- Monteiro, A.; *see* Jenner, F.A.
- Morris, L. Poetry [description of patient experience], 8(3):552-553, 1982.
- Moylan, J.; *see* Wilson, I.C.
- Mueser, K.T., and Dysken, M.W. Narcotic antagonists in schizophrenia: A methodological review, 9(2):213-225, 1983.
- N**
- Nelson, W.; *see* Wilson, I.C.
- Norwind, B.L. Developing an enforceable "right to treatment" theory for the chronically mentally disabled in the community, 8(4):642-651, 1982.
- P**
- Paul, R., and Cohen, D.J. Communication development and its disorders: A psycholinguistic perspective, 8(2):279-293, 1982.
- Pauls, D.L., and Kidd, K.K. Genetic strategies for the analysis of childhood behavioral traits, 8(2):253-266, 1982.
- Peterson, R. What are the needs of chronic mental patients?, 8(4):610-616, 1982.
- Potkin, S.G.; *see* Cannon-Spoor, H.E.
- Prange, A.J., Jr.; *see* Wilson, I.C.
- Pringle, J., and Pyke-Lees, P. Voluntary action by relatives and friends of schizophrenia sufferers in Britain, 8(4):620-625, 1982.
- Proctor, L.R.; *see* Levy, D.L.
- Prosen, M.; *see* Harrow, M.
- Prusoff, B.A.; *see* Jagger, J.
- Pulver, A.E., and Carpenter, W.T., Jr. Lifetime psychotic symptoms assessed with the DIS, 9(3):377-382, 1983.
- Pyke-Lees, P.; *see* Pringle, J.
- R**
- Rosen, B.; *see* Engelhardt, D.M.
- Roth, J.A.; *see* Young, J.G.
- Rotnem, D.; *see* Abbott, D.
- S**
- Schanda, H.; Berner, P.; Gabriel, E.; Kronberger, M.L.; and Küfferle, B. The genetics of delusional psychoses, 9(4):563-570, 1983.
- Schechtman, J.; *see* Worland, J.
- Schooler, C., and Spohn, H.E. Social dysfunction and treatment failure in schizophrenia, 8(1):85-98, 1982.
- Schooler, N.R., and Carpenter, W.T., Jr. New drug treatment strategies in schizophrenia: Editorial introduction, 9(4):500-503, 1983.
- Schulz, P.M.; Schulz, S.C.; Dibble, E.; Targum, S.D.; van Kammen, D.P.; and Gershon, E.S. Patient and family attitudes about schizophrenia: Implications for genetic counseling, 8(3):504-513, 1982.
- Schulz, S.C.; *see* Schulz, P.M.
- Shaywitz, B.A.; *see* Harcherik, D.F.
- Shaywitz, B.A.; *see* Hunt, R.D.
- Shaywitz, B.A.; *see* Young, J.G.
- Shaywitz, S.E. The Yale Neuropsychological Assessment Scales, 8(2):360-424, 1982.
- Shaywitz, S.E.; *see* Harcherik, D.F.
- Shaywitz, S.E.; *see* Hunt, R.D.
- Shaywitz, S.E.; *see* Young, J.G.
- Silverman, L.H.; *see* Mendelsohn, E.
- Snyder, K.S.; *see* Vaughn, C.E.
- Snyder, S.H. What is schizophrenia?, 8(4):595-597, 1982.
- Spitzer, R.L. Letter to the editor, 8(4):529, 1982.
- Spohn, H.E., and Larson, J. Is eye tracking dysfunction specific to schizophrenia?, 9(1):50-55, 1983.
- Spohn, H.E.; *see* Schooler, C.
- Sprague, M.M.; *see* Young, J.G.
- St. Claire Evans, M.; *see* Carpenter, W.T., Jr.
- Stark, L. Abnormal patterns of normal eye movements in schizophrenia, 9(1):55-72, 1983.
- Strauss, J.S. Comments on Blashfield's article, 8(1):8-9, 1982.
- Strauss, J.S. What is schizophrenia?, 9(1):7-9, 1983.
- Summers, F., and Hersh, S. Psychiatric chronicity and diagnosis, 9(1):122-133, 1983.
- T**
- Targum, S.D.; *see* Schulz, P.M.
- V**
- van Kammen, D.P.; *see* Garbutt, J.C.
- van Kammen, D.P.; *see* Schulz, P.M.
- Vaughan, H.G., Jr.; *see* Friedman, D.

Vaughn, C.E.; Snyder, K.S.; Freeman, W.; Jones, S.; Falloon, I.R.H.; and Liberman, R.P. Family factors in schizophrenic relapse: A replication, 8(2):425-426, 1982.

Venables, P.H.; *see* Calev, A.

von Zerssen, D.; *see* Möller, H.-J.

W

Wagner, R.L.; *see* Weinberger, D.R.

Waldo, M.C.; *see* Young, J.G.

Wallace, C.J.; *see* Guy, J.D.

Walters, G.D. The MMPI and schizophrenia: A review, 9(2):226-246, 1983.

Weeks, D.G.; *see* Worland, J.

Weinberger, D.R.; Wagner, R.L.; and Wyatt, R.J. Neuropathological studies of schizophrenia: A selective review, 9(2):193-212, 1983.

Weiner, S.M.; *see* Worland, J.

Werner-Eilert, K.; *see* Möller, H.-J.

Willis, M.J. The impact of schizophrenia on families: One mother's point of view, 8(4):617-619, 1982.

Wilson, I.C.; Garbutt, J.C.; Lanier, C.F.; Moylan, J.; Nelson, W.; and Prange, A.J., Jr. Is there a tardive dyskinesia?, 9(2):187-192, 1983.

Wing, J. What is schizophrenia?, 9(4):497-499, 1983.

Worland, J.; Weeks, D.G.; Weiner, S.M.; and Schechtman, J. Longitudinal, prospective evaluations of intelligence in children at risk, 8(1):135-141, 1982.

Wüschner-Stockheim, M.; *see* Möller, H.-J.

Wyatt, R.J.; *see* Cannon-Spoor, H.E.

Wyatt, R.J.; *see* Weinberger, D.R.

Y

Young, J.G., and Cohen, D.J. Thyroid function in developmental disorders, 8(2):294-296, 1982.

Young, J.G.; Cohen, D.J.; Shaywitz, S.E.; Caparulo, B.K.; Kavanagh, M.E.; Hunt, R.D.; Leckman, J.F.; Anderson, G.M.; Detlor, J.; Harcherik, D.; and Shaywitz, B.A. Assessment of brain

function in clinical pediatric research: Behavioral and biological strategies, 8(2):205-235, 1982.

Young, J.G.; Feiz, R.; Roth, J.A.; Waldo, M.C.; and Cohen, D.J. Catecholamine-thyroid hormone interactions: I. Thyroid hormone and platelet MAO activity in psychiatrically disturbed children, 8(2):297-300, 1982.

Young, J.G.; Kyprie, R.M.; and Cohen, D.J. Catecholamine-thyroid hormone interactions: III. Serum DBH activity and thyroxine in euthyroid subjects, 8(2):306-309, 1982.

Young, J.G.; Sprague, M.M.; Cohen, D.J.; Roth, J.A.; and Genel, M. Catecholamine-thyroid hormone interactions: II. Thyroid hormone and platelet MAO activity in patients with thyroid disorders, 8(2):301-305, 1982.

Young, J.G.; *see* Anderson, G.M.

Z

Zubin, J. What is schizophrenia?, 9(3):331-334, 1983.

Subject Index

A

Abnormal Involuntary Movement Scale (AIMS), 9:187

Age

- Eye tracking, schizophrenia, 9:13, 9:37
- Minnesota Multiphasic Personality Inventory (MMPI), schizophrenia, 9:226
- Neuropsychiatric assessment, children, 8:349
- Psychiatric chronicity, 9:122
- Social behavior, posttreatment, 8:85
- Vestibular reactivity, children, 9:383

Affective Disorders

- Dichotic listening, schizophrenia, affective disorders, 9:134
- IQ, children of parents with affective disorders, 8:135
- Psychotic syndromes, pattern of symptom remission, 9:95

Anomalies, Minor, Physical, in schizophrenia, 9:571

Anxiety

- Social skills training, 8:69

Aphasia

- Pseudo-depression in schizophrenia, 8:118; (letter) 8:594

Attention

- Evoked potentials in children at risk for schizophrenia, 8:514
- Eye tracking in schizophrenia, 9:13; 9:37
- Neuropsychiatric assessment, children, 8:349
- Reaction time, children at risk for schizophrenia, 8:514
- Tourette's syndrome, vigilance tracking task, 8:356

Attention Deficit Disorder

- Clonidine therapy, 8:236
- Diagnostic criteria, 8:236
- Eye tracking deficits, 9:50
- Family and genetic studies, 8:236
- Methylphenidate pharmacokinetics, 8:236
- Social behavior, 8:236

Atypical Psychoses

- Genetic study of relatives of patients with paranoid psychoses, 9:563

Autism. *See* Infantile Autism

Autobiographical Accounts

- Chronic mental patients, 8:610
- Expectations and the recovery process, 8:605
- A father's thoughts, 9:439
- A glimmer of light in the dark, 9:284
- Impact of schizophrenia on families: One mother's point of view, 8:617
- A pharmacy student's view, 9:152
- Poetry, 8:552
- Posthospital adjustment, 8:548
- What I wanted to know but was afraid to ask, 9:583

B

Biochemical factors

- Adenylate cyclase, schizophrenia, 8:438
- Amine metabolites, cerebrospinal fluid, autistic children, 8:205
- Catecholamine metabolites, schizophrenia, 8:438
- Catecholamines, plasma and urinary, infantile autism, 8:205
- Clonidine challenge, infantile autism, 8:205
- Dopamine hypothesis, 8:438; 8:595; 9:325; 9:555
- Dopamine, post-mortem brains of schizophrenics, 8:438
- Dopamine receptor sensitivity, schizophrenia, 8:438
- Dopamine-beta-hydroxylase, infantile autism, 8:205
- Dopamine-beta-hydroxylase, schizophrenia, 8:438
- Dopamine-beta-hydroxylase, thyroxine, children with psychiatric disorders, 8:306
- Environmental factor interaction model, 8:435
- Etiology of schizophrenia, parents' perception, 8:504
- Gamma-aminobutyric acid, cerebrospinal fluid, schizophrenia, 9:336
- Gamma-aminobutyric acid, dopamine interactions, schizophrenia, 9:336

Gamma-aminobutyric acid (GABA), GABA receptor binding, schizophrenic brain, 9:336

Glutamic acid decarboxylase, schizophrenic brain, 9:336

High performance liquid chromatography methodology, 8:333

Homovanillic acid, cerebrospinal fluid, attention deficit disorder, 8:236

Homovanillic acid, cerebrospinal fluid, autistic children, 8:205

Homovanillic acid, post-mortem brains of schizophrenics, 8:438

Human growth hormone, attention deficit disorder, 8:236

Human growth hormone, neuroleptics in schizophrenia, 8:236

5-Hydroxyindoleacetic acid, cerebrospinal fluid, attention deficit disorder, 8:236

5-Hydroxyindoleacetic acid, cerebrospinal fluid, autistic children, 8:205

3-Methoxy-4-hydroxyphenethyleneglycol, attention deficit disorder, 8:236

3-Methoxy-4-hydroxyphenethyleneglycol, cerebrospinal fluid, autistic children, 8:205

Methylphenidate pharmacokinetics, attention deficit disorder, 8:236

Monoamine oxidase, attention deficit disorder, 8:236

Monoamine oxidase, platelets, thyroxine, children with psychiatric disorders, 8:297

Monoamine oxidase, platelets, thyroxine, children with thyroid disorders, 8:297

Monoamine oxidase activity, platelets, schizophrenia, 8:438

Neuroendocrinology, dopaminergic activity assessment, schizophrenia, 8:438

Probenecid blockade, autism, 8:205

Serotonin, attention deficit disorder, 8:236

Temporal lobe epilepsy, dopaminergic supersensitivity, 9:325

Thyroxine, children with psychiatric disorders, 8:297

Tyrosine hydroxylase, schizophrenia, 8:438

C

Caloric Stimulation. See Vestibular Dysfunction

Catatonia

Opioid antagonists in schizophrenia, 9:213

Cerebellar Atrophy in Schizophrenia

Computed tomography scans, 9:193; 9:265

Vermis measurement, post-mortem brains, 9:193

Vestibular dysfunction, 9:383

Cerebrospinal Fluid

Gamma-aminobutyric acid in schizophrenia, 9:336

High performance liquid chromatography methodology, 8:333

Homovanillic acid, attention deficit disorder, 8:236

Homovanillic acid, schizophrenia, 8:438

Probenecid blockade, amine metabolites, children, 8:205

Cognition

Evoked potentials, children at risk for schizophrenia, 8:514

Memory pathology, schizophrenia, 9:247

Neuropsychiatric assessment, children, 8:349

Social skills training, 8:69

Tardive dementia, schizophrenia, 9:187

Thought disorder, speech disorder, schizophrenia, 8:587

Communication

Developmental disorders of language, 8:279

Speech disorder and thought disorder, 8:587

Community Psychiatry

Case management, chronically mentally disabled, 8:655

Dissatisfaction with mental health system, 8:652

Family evaluation of mental health professionals, 8:626

National Schizophrenia Fellowship, 8:620

Pharmacotherapy, psychosocial therapy interaction, 9:543

Right to treatment, 8:642

Community Support Systems

Definition, operational, 8:39

Outcome assessment, 8:39

Computed Tomography in Schizophrenia, 9:193; 9:265

Premorbid adjustment, 8:470

D

Definitions

What is schizophrenia, opinions from authorities, 8:433; 8:595; 9:7; 9:331; 9:495

Deinstitutionalization

Hospitalization rates, schizophrenia, 8:493

Outcome assessment, 8:39

Delusions

Paranoid psychoses, first degree relatives, 9:563

Dementia

Tardive dementia, schizophrenia, 9:187

Depression

Postpsychotic depression, schizophrenia, 8:118

Pseudo-depression, schizophrenia, 8:118; (letter) 8:594

Schizophrenic or paranoid psychoses, 8:109

Development

Motor skills, normal children, 8:349

Neuropsychiatric assessment, 8:349

Premorbid Adjustment Scale, schizophrenia, 8:470

Schizophrenia, triggering life events, 8:600

Tourette's children, motor skills, 8:356

Diagnostic Criteria

Assessment, children, 8:205

Attention deficit disorder, 8:236

Citation analysis, Feighner et al. article, 8:1; (letters) 8:592

DSM-III, Minnesota Multiphasic Per-

- sonality Inventory, schizophrenia, 9:226
- DSM-III criteria, symptoms of Kraepelin and Bleuler, 8:597
- Evoked potentials, diagnostic specificity, 8:514
- Eye tracking, 9:50
- Feighner criteria, 8:1
- Invisible college, 8:1
- Minnesota Multiphasic Personality Inventory, schizophrenia, 9:226
- Research Diagnostic Criteria, 8:1
- Tourette's syndrome, 8:267
- Diagnostic Interview Schedule**
- Lifetime psychotic symptom assessment, 9:377
- Dichotic Listening.** *See* Hemispheric Processing
- Dreams, Hallucinogenic Drug States, and Schizophrenia,** 9:73
- Drug Therapy.** *See* Pharmacotherapy
- Dyskinesia, Tardive**
- Abnormal Involuntary Movement Scale (AIMS), emotional behavior, schizophrenia, 9:187
- Children, neuroleptic withdrawal, 8:320
- Dementia, schizophrenia, 9:187
- Dopamine receptor supersensitivity, 9:555
- Low dose neuroleptics, outcome on Simpson Scale, 9:528
- E**
- Ethics of Research**
- Child psychiatry, 8:205
- Evoked Potentials**
- Children at risk for schizophrenia, 8:514
- Eye Tracking**
- Assessment of dysfunction, 9:44
- Computed tomography, schizophrenia, 9:265
- Editorial introduction, 9:11
- Methodological consensus: Workshop contributions, 9:33
- Review of eye movement dysfunction, 9:13
- Saccadic movements and multilevel control, 9:55
- F**
- Family Studies**
- Attention deficit disorder, 8:236
- Eye tracking, schizophrenia, 9:13
- Family attitudes, schizophrenia, 8:504; 8:626
- IQ, children of parents with schizophrenia, 8:135
- Family Treatment**
- Supportive family counseling, 8:634
- G**
- Genetics**
- Attention deficit disorder, 8:236
- Childbearing attitudes, patients with schizophrenia, 8:504
- Childhood behavioral traits, 8:253
- Counseling, family attitudes, schizophrenia, 8:504
- Evoked potentials, children at risk for schizophrenia, 8:514
- Eye tracking, schizophrenia, 9:13
- Organomorphic patients' first-degree relatives, 9:563
- Paranoid psychoses, first-degree relatives, 9:563
- Stuttering, 8:253
- Tourette's syndrome, 8:253
- Global Assessment Scale**
- Outcome assessment, schizophrenic or paranoid psychoses, 8:99
- Grants, Research.** *See* National Institute of Mental Health
- H**
- Hallucinations**
- Diagnostic Interview Schedule, Present State Examination, compared, 9:377
- Dreams, drug states, schizophrenia, 9:73
- Opioid antagonists, schizophrenia, 9:213
- Outcome, Global Assessment Scale, Inpatient Multidimensional Psychiatric Scale, 8:99
- Hemispheric Processing**
- Computed tomographic measurement, asymmetries, schizophrenia, 9:193; 9:265
- Dichotic listening, schizophrenia, affective illness, 9:134
- Motor skills, normal children, 8:349
- Staggered Spondaic Word Test in psychosis, 9:134
- Heterogeneity**
- Dichotic listening, schizophrenia, affective illness, 9:134
- Dopamine receptor binding, dynamic change, schizophrenia, 9:325
- Evoked potentials, high-risk children, 8:514
- Genetic study, relatives of patients with paranoid psychoses, 9:563
- Multiple central nervous system abnormalities, 8:433
- Neuroleptic response, schizophrenia, 8:429
- Pharmacotherapeutic response, 9:504
- High Performance Liquid Chromatography (HPLC)**
- Measurement of neurochemistry, 8:333
- Hippocampus, Atrophy in Schizophrenia,** 9:193
- I**
- Infantile Autism**
- Amine metabolites, cerebrospinal fluid, 8:205
- Catecholamines, plasma, urine, 8:205
- Clonidine challenge, 8:205
- Dopamine-beta-hydroxylase, 8:205
- Psychophysiology, 8:205
- Information Processing**
- Social skills training, 8:62
- Inpatient Multidimensional Psychiatric Scale (IMPS)**
- Depression, schizophrenia, 8:109

Outcome assessment, schizophrenic or paranoid psychoses, 8:99

K

Katz Adjustment Scales and psychiatric chronicity, 9:122

L

Language. *See* Communication

Laterality. *See* Hemispheric Processing

Lysergic Acid Diethylamide, PGO waves and hallucinations, 9:73

M

Memory. *See* Cognition

Minnesota Multiphasic Personality Inventory (MMPI), schizophrenia, 9:226

Monoamine Oxidase

- Attention deficit disorder, platelet activity, 8:236
- Inhibitors, clinical effects, schizophrenia, 8:438
- Schizophrenia, platelet activity, 8:438
- Thyroxine, children with psychiatric disorders, 8:297
- Thyroxine, children with thyroid disorders, 8:297

N

National Institute of Mental Health (NIMH)

- Schizophrenia-related research grants, fiscal year 1980, 8:142
- Schizophrenia-related research grants, fiscal year 1981, 9:443

Neuroleptics

- Aphanisis, schizophrenia, 8:118
- Computed tomographic measures of ventricular enlargement, neuroleptics, 9:265
- Dopamine receptor supersensitivity reviewed, 9:555
- Eye tracking, schizophrenia, 9:13; 9:37
- Human growth hormone, methylphenidate, schizophrenia, 8:236

Low dose neuroleptics, outcome, 9:528

- Nonresponders to neuroleptics, symptom differences, 8:429
- Pseudo-depression, schizophrenia, 8:118
- Receptor binding, post-mortem brains of schizophrenics, 8:438
- Seizure threshold, children treated with neuroleptics, 8:320
- Symptom remission pattern, treatment response, 9:95
- Tardive dementia, schizophrenia, 9:187
- Tardive dyskinesia, low dose neuroleptics, 9:528
- Time-limited pharmacotherapy, patients followed drug free, 9:533

Neurological Impairment and minor physical anomalies in schizophrenia, 9:571

Neuropathology in Schizophrenia, 9:193

Nystagmus Abnormalities in Schizophrenia, 9:383

O

Onset Age and minor physical anomalies, 9:571

Opioid Peptides

Naloxone and naltrexone treatment of schizophrenia, 9:213

Outcome

- Antipsychotic medication, social behavior, 8:85
- Burn-out, postpsychotic depression, schizophrenia, 8:118
- Childbearing attitudes, patients with schizophrenia, 8:504
- Community support systems, 8:39
- Demographic characteristics, 9:122
- Disability, most troubling characteristics rated by patients, parents, and siblings, 8:504
- First-rank symptoms, multiple regression, 9:1
- Global Assessment Scale, impairment, symptoms, 8:99
- Hallucinations, excitement, 8:99
- Hospitalization, chronic schizophrenia, 8:493
- Hospitalization length, premorbid adjustment in schizophrenia, 8:470; 8:493

Hospitalization rates, schizophrenia, 8:493

- Lifetime psychotic symptom assessment, Diagnostic Interview Schedule, 9:377
- Measurement instruments, 8:13
- Neuroleptics, nonresponse or deterioration, 8:429
- Paranoid psychoses, prediction, 8:99
- Phillips Prognostic Rating Scale, 8:470
- Postpsychotic depression, schizophrenia, 8:118
- Preadmission hospitalization history, 8:493
- Recovery from schizophrenia, patterns of psychosis, 9:95
- Self-ratings, schizophrenic or paranoid psychoses, 8:99
- Skills training, 8:13; 8:69
- Social adjustment, 8:85; 8:99
- Time-limited pharmacotherapy, patients followed drug free, 9:533

P

Pervasive Developmental Disorders

- Neuroleptic treatment, 8:320
- Seizure threshold, children treated with neuroleptics, 8:320
- Tardive dyskinesia, children with neuroleptic withdrawal, 8:320

PGO Waves and hallucinogenic drug states, 9:73

Pharmacotherapy

- Alpha-methyl-para-tyrosine (AMPT), schizophrenia, 8:438
- Amphetamine, schizophrenic children, 8:320
- Antidepressants, schizophrenia, 9:504
- Baclofen trials, schizophrenia, 9:336
- Benzodiazepines, schizophrenia, 9:504
- Carbamazepine, schizophrenia, 9:504
- Clonidine, attention deficit disorder, 8:236
- Clonidine, schizophrenia, 9:504
- Clonidine, Tourette's syndrome, 8:205
- Depression, neuroleptics, schizophrenia, 8:109
- Dopamine agonists, review of clinical effects, schizophrenia, 8:438
- Eye tracking, schizophrenia, 9:13

GABAergic drug trials, schizophrenia, 9:336
 Haloperidol, pervasive developmental disorders, 8:320
 Haloperidol, Tourette's syndrome, 8:267
 Human growth hormone treatment of hypopituitary children, 8:310
 L-Dopa, schizophrenic children, 8:320
 Lithium, pervasive developmental disorders, 8:320
 Lithium, schizophrenia, 9:504
 Low dose neuroleptics, outcome, 9:528
 Methylphenidate pharmacokinetics, attention deficit disorder, 8:236
 Minnesota Multiphasic Personality Inventory, schizophrenia, treatment response, 9:226
 Monoamine oxidase inhibitors, schizophrenia, 8:438
 Naloxone, schizophrenia, 9:213
 Naltrexone, schizophrenia, 9:213
 Neuroleptics, depression, schizophrenia, 8:109
 Neuroleptics, nonresponse or deterioration, 8:429
 Neuroleptics, pervasive developmental disorders, 8:320
 Neuroleptics reviewed, 9:504
 Outcome measurement, 8:13
 Pharmacokinetics, neuroleptics in children, 8:320
 Propranolol, schizophrenia, 9:504
 Psychosocial therapy interaction, 9:543
 Social behavior, neuroleptics, 8:85
 Tardive dyskinesia, children with neuroleptic withdrawal, 8:320
 Time-limited pharmacotherapy, patients followed drug free, 9:533
 Tourette's syndrome, haloperidol, 8:267

Pneumoencephalographic Studies in Schizophrenia, 9:193

Positive/Negative Symptoms

Nurses Observation Scale for Inpatient Evaluation (NOSIE) for assessment, 9:368
 Recovery from schizophrenia and patterns of psychosis, 9:95
 Reliability, temporal stability, Schedule for Affective Disorders-Change Version (SADS-C) and NOSIE assessment, 9:368

SADS-C interview, symptom assessment, 9:368

Premorbid Adjustment

Acute vs. insidious onset, schizophrenia, 8:470
 Computed tomography, schizophrenia, 8:470
 Phillips Prognostic Rating Scale, 8:470
 Premorbid Adjustment Scale (PAS), schizophrenia, 8:470
 Premorbid function, minor physical anomalies, schizophrenia, 9:571

Process/Reactive Dimension and minor physical anomalies in schizophrenia, 9:571

Psychophysiology

Attention deficit disorder, 8:236
 Electroencephalographic abnormalities, Tourette's syndrome, 8:267
 Evoked potentials, children at risk for schizophrenia, 8:514
 Eye tracking, schizophrenia, 9:11
 Infantile autism, 8:205
 Smooth pursuit eye movements, schizophrenia, 9:11

Psychotic Experience

Fantasy activation, thought disorder, 8:532

R

Race

Minnesota Multiphasic Personality Inventory, schizophrenia, 9:226

Rapid Eye Movement (REM) Sleep

Dreams, hallucinogenic drug states, and schizophrenia, 9:73

Rehabilitation

Community support systems, 8:39
 Measurement instruments, 8:13; 8:39
 Skills training measures, 8:13

Research

Child psychiatry, methods and strategies, 8:201; 8:205; 8:236; 8:253
 Interview reliability, 8:485

Narrative information, consensus ratings, 8:485
 Neuropsychiatric assessment, childhood, 8:201
 Self-rating/observer rating correlations, 8:485
 Social skills instruments, tabular listing, 8:62
 Structured psychiatric interviews, 8:485
 Symptom rating concordance, 8:485
 Yale Neuropsychoeeducational Assessment Scale, scoring forms, description, 8:360

S

Schizoaffective Psychoses

IQ in children of patients, 8:135

Schizophrenic Process

Definition of schizophrenia, 9:7
 Fantasy and thought disorder, 8:532
 Symptom remission patterns, 9:95

Schizophrenic Subtypes

Computed tomography, schizophrenia, 9:265
 Premorbid Adjustment Scale (PAS), schizophrenia, 8:470

Sex Differences

Homovanillic acid, cerebrospinal fluid, children, 8:205
 IQ, children of ill mothers and ill fathers with schizophrenia, 8:135
 Minnesota Multiphasic Personality Inventory, schizophrenia, 9:226
 Motor skills, normal children, 8:349
 Verbal behavior, intermingling, schizophrenia, 9:354

Social Behavior

Adjustment, Global Assessment Scale, 8:99
 Antipsychotic medication, 8:85
 Attention deficit disorder, 8:236
 Demographic characteristics, psychiatric chronicity, 9:122
 Interaction observations, 8:85
 Low dose neuroleptics, social adjustment, 9:528
 Measurement technology, 8:62

Resocialization program for chronic schizophrenics, 8:85
Tourette's syndrome, 8:267

Social Class

IQ, children of patients with schizophrenia, 8:135

Social Skills Training

Assessment, 8:13, 8:62
Nonverbal elements, 8:62
Pharmacotherapy, psychosocial therapy interaction, 9:543

Statistics

First-rank symptoms, multiple regression, 9:1
Rasch model, positive/negative symptom assessment, 9:368

Subtypes; *see also* Schizophrenic Subtypes

Paranoid psychoses, outcome prediction, 8:99

Symptoms Checklist (SCL)-90 and psychiatric chronicity, 9:122

T

Tardive Dyskinesia. *See* Dyskinesia, Tardive

Thought Disorder

Demographic variables, verbal behavior, 9:354
Fantasy activation, 8:532
Intermingling, loss of set, schizophrenia, 9:354
Speech disorder, nonspeech disorder, 8:587
Verbal behavior, schizophrenia, 9:354

Thyroid Function

Adrenergic system modulation, 8:294
Dopamine-beta-hydroxylase, thyroxine, children with psychiatric disorders, 8:306
Monoamine oxidase, platelets, thyroxine, 8:297

Tourette's Syndrome

Attention, vigilance tracking task, 8:356
Clinical assessment instruments, 8:205
Clonidine treatment, 8:205
Cognitive function, 8:356
Epidemiology, 8:267
Genetic analysis, 8:253; 8:267
Haloperidol treatment, 8:267
Symptomatology, 8:267
Wechsler Intelligence Scale for Children (WISC) subtests, 8:356

Twin Studies

Eye tracking, schizophrenia, 9:13

V

Ventricular Size in Schizophrenia, 9:193; 9:265

Verbal Behavior. *See* Thought Disorder

Vestibular Dysfunction in Schizophrenia, 9:383

Vulnerability

Evoked potentials in children at risk for schizophrenia, 8:514
Life events and development, 8:600
Pharmacotherapy and psychosocial therapy interaction, 9:543

W

Wechsler Adult Intelligence Scale (WAIS)

Physical anomalies in schizophrenia, 9:571
Psychological functioning in resocialization program for chronic schizophrenics, 8:85

Wechsler Intelligence Scale for Children (WISC)

Offspring of families with one schizophrenic parent, 8:135

What Is Schizophrenia?

Opinions from authorities, 8:433; 8:595; 9:7; 9:331; 9:495

Y

Yale Neuropsychoevaluational Assessment Scales, 8:372